News | May 10, 2011

International Launch Begins for Smallest CRT-Ds, ICDs to Treat Heart Failure

May 10, 2011 – The world's smallest and thinnest high-energy cardiac resynchronization therapy defibrillators (CRT-Ds) and implantable cardioverter defibrillators (ICDs) to treat heart failure and sudden cardiac death and offer excellent longevity were launched this week in Europe. Boston Scientific Corp. announced the launch and first implants of its Energen and Punctua CRT-Ds and ICDs in Europe and other international markets.

"These devices build on the technological advancements of Cognis and Teligen by providing options to customize therapy for individual patients," said Professor Joachim Winter, M.D., who performed one of the first implants of the Energen ICD with Dong-In Shin, M.D., at the University Hospital Dusseldorf in Germany. "The small profile, coupled with the 4-Site connector system, allowed for an easy implant with a less pronounced physical appearance for the patient."

"Physicians and patients will truly appreciate the longevity of these devices since it may reduce the need for additional implant surgeries," said Peter Lecher, M.D., who performed one of the first implants of the Energen CRT-D with Gunther Prenner, M.D., at the Medical University in Graz, Austria. "Additionally, the new therapy options, combined with the Latitude patient management system, increase the variety of diagnostic parameters to help treat heart failure patients."

Most of the new Energen and Punctua devices offer the 4-Site DF4 connector system option, designed to simplify the implant procedure and comply with international connector standards. Additionally, nearly all models are compatible with Boston Scientific's Latitude patient management system, which enables physicians to remotely monitor implantable cardiac device patients between on-site office visits.

The company received CE mark approval for its Energen and Punctua CRT-Ds and ICDs in October 2010. In the United States, they are investigational devices, limited by applicable law to investigational use and not available for sale. The company expects U.S Food and Drug Administration (FDA) approval for the devices in late 2011 or early 2012.

For more information: www.bostonscientific.com

Related Content

Medtronic Begins Pilot Study of Investigational Extravascular ICD System
News | Implantable Cardioverter Defibrillator (ICD) | August 09, 2018
Medtronic plc announced the start of a pilot study of its investigational Extravascular Implantable Cardioverter...
ICD Placements Not Meeting Medicare Coverage Criteria Decline After Overuse Investigation Announced
Feature | Implantable Cardioverter Defibrillator (ICD) | July 11, 2018
Placement of implantable cardioverter defibrillators (ICDs) not meeting Centers for Medicare and Medicaid Services (CMS...
New Tool Predicts Benefits and Risks of Implantable Defibrillator for Heart Failure Patients
News | Implantable Cardioverter Defibrillator (ICD) | July 02, 2018
University of Washington (UW) Medicine cardiologists have developed a tool to predict which heart-failure patients...
Real-World Data Demonstrates Success Of Smart Pass Filter on Boston Scientific S-ICD System
News | Implantable Cardioverter Defibrillator (ICD) | May 16, 2018
Boston Scientific announced results from an analysis of the LATITUDE database evaluating the successful reduction of...
Online Message Board Advice on ICDs Reflects Inaccuracies
News | Implantable Cardioverter Defibrillator (ICD) | April 13, 2018
April 13, 2018 — Medical advice about implanted cardiac defibrillators obtained via an online message board appears t
Biotronik U.S. to Distribute Aziyo ECM Envelopes
News | Implantable Cardioverter Defibrillator (ICD) | April 12, 2018
Biotronik U.S. and Aziyo announced a strategic agreement allowing Biotronik to distribute Aziyo's CanGaroo...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD) | September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD) | September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillator (ICD) | July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Videos | Implantable Cardioverter Defibrillator (ICD) | June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
Overlay Init